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Type I IFN Inhibits Alternative Macrophage Activation
during Mycobacterium tuberculosis Infection and Leads to
Enhanced Protection in the Absence of IFN-g Signaling
Lu´cia Moreira-Teixeira,*,†,1 Jeremy Sousa,*,‡,1 Finlay W. McNab,†,2 Egı´dio Torrado,*
Filipa Cardoso,* Henrique Machado,* Fla´via Castro,* Vaˆnia Cardoso,* Joana Gaifem,*
Xuemei Wu,† Rui Appelberg,‡,x Anto´nio Gil Castro,* Anne O’Garra,†,{,1 and
Margarida Saraiva*,‡,‖,1
Tuberculosis causes ∼1.5 million deaths every year, thus remaining a leading cause of death from infectious diseases in the world.
A growing body of evidence demonstrates that type I IFN plays a detrimental role in tuberculosis pathogenesis, likely by
interfering with IFN-g–dependent immunity. In this article, we reveal a novel mechanism by which type I IFN may confer
protection against Mycobacterium tuberculosis infection in the absence of IFN-g signaling. We show that production of type I
IFN byM. tuberculosis–infected macrophages induced NO synthase 2 and inhibited arginase 1 gene expression. In vivo, absence of
both type I and type II IFN receptors led to strikingly increased levels of arginase 1 gene expression and protein activity in infected
lungs, characteristic of alternatively activated macrophages. This correlated with increased lung bacterial burden and pathology
and decreased survival compared with mice deficient in either receptor. Increased expression of other genes associated with
alternatively activated macrophages, as well as increased expression of Th2-associated cytokines and decreased TNF expression,
were also observed. Thus, in the absence of IFN-g signaling, type I IFN suppressed the switching of macrophages from a more
protective classically activated phenotype to a more permissive alternatively activated phenotype. Together, our data support a
model in which suppression of alternative macrophage activation by type I IFN during M. tuberculosis infection, in the absence of
IFN-g signaling, contributes to host protection. The Journal of Immunology, 2016, 197: 4714–4726.
T
uberculosis (TB), caused by Mycobacterium tuberculosis
infection, is a leading cause of mortality and morbidity,
causing ∼1.5 million deaths every year (1). Despite the
efforts devoted to the understanding of this disease, mechanisms
determining whether protection or pathogenesis results from
M. tuberculosis infection remain poorly understood. An in-depth
understanding of these mechanisms is critical for the design of
novel preventive and therapeutic strategies based on the modu-
lation of the immune response.
The initiation of the immune response to M. tuberculosis relies
on bacterial recognition by pattern recognition receptors, such as
TLR, by host sentinel cells (2). Recognition of M. tuberculosis
triggers the production of key cytokines, chemokines, and anti-
microbial molecules that are crucial to activate microbicidal
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mechanisms in innate immune cells and for the establishment of
the adaptive immune response, restriction of bacterial growth, and,
ultimately, host resistance (3–6). Among key cytokines produced
by innate immune cells, IL-12 is critical for the induction of pro-
tective Th1 responses and IFN-g production (5, 7–9). In turn, IFN-g
is crucial for full activation of macrophages, enhancing the pro-
duction of cytokines and expression of microbicidal mediators, such
as the inducible isoform of the enzyme NO synthase (NO synthase
2 [NOS2]) that is critical for controlling bacterial growth (9–13).
Indeed, mice deficient in IFN-g (Ifng2/2 mice) or NOS2 (Nos22/2
mice) are extremely susceptible to M. tuberculosis infection, sup-
porting the essential role of IFN-g and NO in immunity against
M. tuberculosis infection (10–14).
Different strains of M. tuberculosis interact with host TLRs in a
distinct way, which is likely to shape the downstream immune
response and disease outcome. We recently showed that, although
most of the M. tuberculosis strains tested primarily activate TLR2,
some activate TLR4 (15). TLR4 activation by M. tuberculosis was
found to result in the expression of host-protective factors (e.g.,
TNF, IFN-g, and NOS2) and to limit bacterial growth during
in vivo infection (15). Despite the protective role of TLR4, a
hypervirulent strain of M. tuberculosis recognized predominantly
by this receptor was also found to induce high levels of type I IFN
during infection (15), a cytokine that was associated with exac-
erbated disease (16, 17). Infection with other hypervirulent strains
of M. tuberculosis showed a correlation between increased levels
of type I IFN and increased virulence in mouse models of
M. tuberculosis infection (18–20). M. tuberculosis infection of
mice deficient in the type I IFN receptor (IFNAR) (Ifnar2/2 mice)
largely results in reduced bacterial load and/or increased survival
compared with wild-type (WT) mice (19–22). Additionally,
overexpression of type I IFN during M. tuberculosis infection
provided robust evidence for the detrimental effects of type I IFN
during TB (18, 23–26). Induction of high levels of type I IFN by
direct instillation of type I IFN (18) or a type I IFN inducer (23, 25)
into the lungs of M. tuberculosis–infected mice promoted disease
severity. Abrogation of a negative regulator of type I IFN signaling
increased host susceptibility to M. tuberculosis infection (24).
Coinfection of mice with influenza A virus and M. tuberculosis
resulted in increased bacterial loads in a type I IFN–dependent
manner (26). Furthermore, a potential negative role for type I IFN
was also revealed in human TB, because patients with active TB
showed a prominent type I IFN–inducible blood signature (27–30)
that correlated with the extent of radiographic disease (27) and that
diminished upon successful treatment (30, 31). Thus, studies in
mouse and humans highlight a potentially detrimental, rather
than protective, role for type I IFN during TB (16–30).
The mechanisms that mediate type I IFN–dependent TB exac-
erbation are a major topic of investigation in the field (16, 17).
Recent studies described that type I IFN suppresses the expression
of protective proinflammatory cytokines (e.g., IL-1, TNF, and
IL-12) while inducing the immune-suppressive cytokine IL-10
during M. tuberculosis infection (18–21, 32–34). Generation and
trafficking to the lung ofM. tuberculosis–permissive myeloid cells
in response to induced type I IFN may also contribute to exac-
erbated disease (22, 23, 35). Type I IFN also was shown to impair
Th1 cell responses in in vivo mouse models (18, 20, 32, 36) and to
inhibit IFN-g–induced antimicrobial responses in murine macro-
phages (33) and human monocytes (37, 38). The interplay be-
tween type I and type II IFN is further supported by a recent report
by Desvignes et al. (39) describing an unanticipated protective
role for type I IFN during M. tuberculosis infection in the absence
of IFN-g signaling. Mice deficient in both type I and type II
IFNRs (Ifngr2/2 3 Ifnar2/2 mice) showed increased pulmonary
pathology and early mortality following M. tuberculosis infection
compared with single type II IFNR–deficient (Ifngr2/2) mice (39).
The investigators unmasked the involvement of type I IFN in the
recruitment and/or survival of myeloid cells into the lungs and
restriction of M. tuberculosis infection of these cells when IFN-g
signaling was absent (39). A putative protective role for type I IFN
in the absence of IFN-g signaling also was suggested in human TB
based on the observation that administration of type I IFN, to-
gether with multidrug antimycobacterial treatment, had beneficial
effects against disseminated Mycobacterium avium infection in a
patient with IFN-gR deficiency (40).
In this article, we describe a novel mechanism for type I IFN in
regulating macrophage activation during infection with a virulent
strain of M. tuberculosis in the absence of IFN-g signaling. Using
a TLR4-activating virulent strain of M. tuberculosis that induces
high levels of type I IFN, we detected increased levels of arginase
1 (Arg1) gene expression in the lungs, along with other genes
associated with alternatively activated macrophages, when IFNAR
signaling was abrogated in IFN-gR–deficient mice following
in vivo infection. This correlated with increased lung bacterial
loads and pathology, as well as increased Th2-associated cytokines
and decreased TNF levels. Thus, our data indicate that suppression
of alternative macrophage activation during M. tuberculosis infec-
tion by type I IFN confers protection against M. tuberculosis in-
fection in the absence of IFN-g signaling.
Materials and Methods
Ethics statement
All animal experiments were performed in strict accordance with the
recommendations of the European Union Directive 2010/63/EU and were
previously approved by the Portuguese National Authority for Animal
Health (Direc¸a˜o Geral de Alimentac¸a˜o e Veterina´ria).
Mice
C57BL/6 WT mice and knockout (KO) mice (all backcrossed $10 gen-
erations to the C57BL/6 background) were bred and housed at the Life and
Health Sciences Research Institute (ICVS) (WT, Tlr22/2 and Tlr42/2
mice), Instituto de Investigac¸a˜o e Inovac¸a˜o em Sau´de (WT, Tnf2/2, Nos22/2
mice), and at The Francis Crick Institute, Mill Hill Laboratory (WT,
Ifnar2/2 and Ifngr2/2 mice). Ifngr2/2 and Ifnar2/2 mice were crossed to
obtain double-KO (dKO) mutant mice (Ifngr2/2 3 Ifnar2/2). Bones
from Il1r2/2 and Ticam2/2 mice (and WT controls) were generously
provided by Dr. Teresa Pais (Instituto de Medicina Molecular, Lisbon,
Portugal) and by Dr. Luigina Romani (University of Perugia, Perugia,
Italy), respectively. Mice were bred and maintained for experiments in
accordance with the European Union Directive 2010/63/EU or the United
Kingdom Home Office regulation and the Animal Scientific Procedures
Act, 1986. For infections with M. tuberculosis, animals were housed
under barrier conditions in the Animal Biosafety Level 3 facility at ICVS.
Mice were matched for sex and age for use in experiments.
Bacteria
M. tuberculosis strains H37Rv Pasteur and BTB 02-171 were kindly
provided by Dr. Pere-Joan Cardona (Experimental Tuberculosis Unit,
Barcelona, Spain) and Dr. Gunilla Ka¨llenius (Karolinska Institutet,
Stockholm, Sweden), respectively. M. tuberculosis strains were grown in
Middlebrook 7H9 liquid media for 7–10 d, diluted into Proskauer Beck
medium with 0.05% Tween 80 for further expansion to mid-log phase, and
frozen in 1-ml aliquots at 280˚C, as previously described (15). All stocks
were checked for endotoxin contamination using the Limulus assay (Sigma)
and found to be negative.
Bone marrow–derived macrophages
Bone marrow–derived macrophages (macrophages) were differentiated
from bone marrow precursors cultured in complete DMEM (containing
10% FBS, 1% sodium pyruvate, 1% HEPES and 1% L-glutamine; all from
Life Technologies) supplemented with 20% L929 cell-conditioned media,
as previously described (15). Briefly, total bone marrow cells were cultured
in microbiological petri dishes (Sterilin) and kept at 37˚C and 5% CO2.
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Cells were fed on day 4 with 4 ml of complete DMEM containing 20%
L929 cell-conditioned media. On day 7, macrophages were harvested,
counted, and seeded into 24-well tissue culture plates (Nunc) at 0.5 3 106
cells per well in culture medium. Cells were infected with M. tuberculosis
strains at a multiplicity of infection (MOI) of 2. In some experiments,
macrophages were stimulated with LPS (0.5 mg/ml; Sigma). When indi-
cated, polymyxin B (5 m/ml; Sigma), cycloheximide (10 mg/ml; Sigma),
rIFN-b (2 ng/ml; PBL), or rIFN-g (5 ng/ml; R&D Systems) was added at
the time of infection. At specific time points postinfection, total RNA was
isolated and/or supernatants were collected.
Enumeration of intracellular M. tuberculosis in macrophages
To determine the number of intracellular M. tuberculosis CFU present in
macrophages following in vitro infection, supernatants were removed, and
macrophages were washed with PBS and lysed with saponin (Sigma). This
suspension was serially diluted and plated onto Middlebrook 7H11 agar
(BD Biosciences) plates containing OADC, and colonies were counted
after 3 wk of incubation at 37˚C. Differences in bacterial uptake among
WT, Tlr42/2, Ifnar2/2, and Nos22/2 macrophages were monitored by
enumerating CFU at 4 h postinfection, with no significant differences
observed (data not shown).
Experimental infection
Mice were infected with M. tuberculosis strains H37Rv or BTB 02-171 via
the aerosol route using an inhalation exposure system (Glas-Col) calibrated
to deliver ∼100–200 CFU to the lungs. The infection dose was confirmed by
determining the number of viable bacteria in the lungs of three to five mice
3 d after the aerosol infection. For bacterial load determination, mice were
euthanized by CO2 inhalation, and the lungs were aseptically excised and
individually homogenized, followed by plating of serial dilutions of the or-
gan homogenate on Middlebrook 7H11 agar (BD Biosciences) supplemented
with OADC and Panta. CFU were counted after 3 wk of incubation at 37˚C.
Quantitative real-time PCR analysis
Total RNA from infected lungs or cultured macrophages was extracted with
TRIzol Reagent (Invitrogen), according to the manufacturer’s instructions.
cDNA was synthesized using the SuperScript First-Strand Synthesis Sys-
tem for RT-PCR (Thermo Scientific). Target gene mRNA expression was
quantified by real-time PCR (Bio-Rad CFX96 Real-Time System with
C1000 Thermal Cycler) and normalized to Hprt1 or Ubiquitin mRNA
levels. Target gene mRNA expression was quantified using SYBR Green
(Thermo Scientific) and specific oligonucleotides (Invitrogen) for Tnf ([F]
59-GCC ACC ACG TCT TCT GTC T-39, [R] 59-TGA GGG TCT GGG
CCATAG AAC-39) and Ubiquitin ([F] 59-TGG CTATTA ATTATT CGG
TCT GCAT-39, [R] 59-GCA AGT GGC TAG AGT GCA GAG TAA-39) or
TaqMan primer probes (Applied Biosystems) for Nos2 (Mm00440502_m1),
Arg1 (Mm00475988_m1), Ym1 (Mm00657889_mH), Fizz1 (Mm00445109_m1),
Il4 (Mm00445260_m1), Il5 (Mm00439646_m1), Il13 (Mm00434204_m1), Il10
(Mm00439614_m1) and Hprt1 (Mm00446968_m1).
Histology
Whole lungs were perfused in situ with PBS. The right upper lobe of in-
fected lungs was excised and fixed in 3.7% phosphate-buffered formalin for
1 wk. Then tissue was embedded in paraffin and cut into 3-mm-thick
sections. Lung specimens were stained with H&E and subjected to mi-
croscopic morphometric analysis. Lung surface area of inflammation was
measured using ImageJ software (version 1.50e; National Institutes of
Health). Briefly, entire lung sections were analyzed, and the areas corre-
sponding to the whole section and individual lesions were manually se-
lected and measured. The percentage of total lung area involved with
inflammation was calculated by dividing the cumulative area of inflam-
mation by the total lung surface area for each sample.
NOS2 detection by immunofluorescence
NOS2 was detected by immunofluorescencewith a rabbit anti-mouse NOS2
primary Ab IgG (M-19; Santa Cruz Biotechnology) and an Alexa Fluor 488
goat anti-rabbit secondary Ab IgG (Invitrogen), as previously described
(15). DAPI was used to detect nuclei. Images were acquired on an
Olympus BX61 fluorescence microscope using Cell^P software.
Measurement of NO production
NO production was quantified in cell culture supernatants by the Griess
reaction. Absorbance was measured at 550 nm using a microplate reader
(Bio-Rad), and NO concentration was assessed using a sodium nitrite
standard curve (0–100 mM analyzed in duplicate).
Arginase activity assay
ARG1 activity in lung homogenates was determined using the Arginase
Activity Assay Kit (Sigma), according to the manufacturer’s instructions.
Briefly, 1 3 106 lung cells were lysed for 10 min in 10 mM Tris-HCl
(Calbiochem) (pH 7.4) containing 1 mM pepstatin A, 1 mM leupeptin, and
0.4% (w/v) Triton X-100 (all from Sigma). Each sample was incubated for
2 h at 37˚C in the presence of assay reagent and then incubated with urea
reagent for 1 h at room temperature. Urea levels were subsequently de-
tected and calculated according to the manufacturer’s instructions. ARG1
activity is expressed as U/l, and data are shown as fold induction relative to
uninfected control mice.
Cytokine determination by ELISA
TNF concentration in the supernatants of infected macrophages was de-
termined by ELISA using a commercially available kit (eBioscience),
according to the manufacturer’s instructions. Cytokine levels from unin-
fected cells were below the assay level of detection (20 pg/ml; data not
shown).
Flow cytometry
Myeloid cell populations from infected lungs were characterized using
flow cytometry. For cell surface staining, Abs against CD11b (M1/70;
eBioscience), CD11c (N418), Ly6G (1A8), and Ly6C (HK1.4; all from
BioLegend) were used. For intracellular staining of NOS2, lung cells were
fixed with 2% paraformaldehyde and permeabilized with 0.5% saponin
(Sigma) before staining with anti-NOS2 Ab (CXNFT; eBioscience).
Samples were acquired on a LSR II flow cytometer with FACSDiva
software (BD Bioscience). Data were analyzed using FlowJo software
(TreeStar).
Statistics
Data are shown as the mean 6 SEM. Statistical tests, as described in the
figure legends, were used to compare experimental groups, with p , 0.05
considered significant. GraphPad Prism 6 (GraphPad) was used for data
analysis and preparation of all graphs.
Results
Early and elevated Nos2 expression induced by infection with
a virulent TLR4-activating strain of M. tuberculosis results in
protection and not pathology
Although it is generally recognized that NOS2 plays an essential
role in the host defense against some strains ofM. tuberculosis (12,
14, 41, 42), other studies assign a detrimental role to NOS2 in the
context of M. avium infection (43) and other bacterial infections
(44, 45). Previous data from our group showed that TLR4 acti-
vation by M. tuberculosis BTB 02-171 induced an early and ele-
vated expression of Nos2 in the lungs of infected mice that was
accompanied by enhanced lung pathology; this was not seen when
the TLR2-activating laboratory reference strain H37Rv was used
(15). To investigate whether early and elevated levels of Nos2 ex-
pression could explain the enhanced pathology, WT and Nos22/2
mice were aerosol infected with M. tuberculosis strain H37Rv or
BTB 02-171. As expected, bacterial loads were significantly
increased in the lungs of H37Rv-infected Nos22/2 mice by day
30 postinfection, but no major differences in lung bacterial loads
were observed at earlier times post-H37Rv infection (days 18
and 24 postinfection) compared with WT mice (Fig. 1A). However,
higher bacterial loads were detected in the lungs at these early
times, in addition to day 30, postinfection with BTB 02-171 in
Nos22/2 mice compared with WT mice (Fig. 1B), in keeping with
an earlier and elevated induction of Nos2 transcription and NOS2
expression (15) (Supplemental Fig. 1). Increased bacterial loads
observed in the absence of NOS2 were accompanied by enhanced
lung pathology, which was quantified by the extent of lung area
with inflammatory lesions at day 24 postinfection (Fig. 1C, 1D),
confirming the protective, rather than detrimental, role of early and
elevated Nos2 levels observed during BTB 02-171 M. tuberculosis
infection.
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TLR4 recognition of a virulent M. tuberculosis strain induces
high Nos2 transcription and NO production by infected
macrophages
To investigate the mechanisms underlying high Nos2 induction,
we infected mouse bone marrow–derived macrophages (macro-
phages) with M. tuberculosis strain H37Rv or BTB 02-171. Nos2
mRNA, NOS2 protein, and NO secretion were strongly upregu-
lated upon macrophage infection with M. tuberculosis strain BTB
02-171, but not H37Rv (Fig. 2A–C), despite similar infection
levels (Supplemental Fig. 2A), thus replicating the in vivo results.
These data suggest that the higher induction of Nos2 by BTB 02-
171 may be a direct response of the macrophage to bacterial li-
gands, which is consistent with the fact that these phagocytes are
among the first cells to recognize M. tuberculosis (4) and are well
known for their capacity to upregulate Nos2 and produce NO as a
bactericidal mechanism (46). Because TLRs are capable of dif-
ferential recognition of M. tuberculosis strains (15), we infected
WT and Tlr22/2 and Tlr42/2 macrophages with the BTB 02-171
strain and measured NO secretion by quantifying the amount of
nitrites in the supernatant 24 h later. TLR2 deficiency led to a
minor reduction in nitrite concentrations; however, the lack of
TLR4 nearly completely abrogated NO production (Fig. 2D). In
line with this, Nos2 transcription was also greatly reduced at 6 h
postinfection in Tlr42/2 and Ticam2/2 macrophages, but not in
Tlr22/2 macrophages, compared with WT controls (Supplemental
Fig. 2B, 2C). The upregulation of Nos2 expression and NO pro-
duction was a direct effect of the mycobacteria, because produc-
tion of NO by BTB 02-171–infected macrophages was not
affected by a concentration of polymyxin B (an endotoxin inhib-
itor) that completely abrogated NO production by macrophages
stimulated with 500 ng/ml of LPS (Supplemental Fig. 2D). TLR4-
dependent Nos2 induction and NO production by infected mac-
rophages were also observed postinfection with M. tuberculosis
strain Harlingen (Supplemental Fig. 2E, 2F), which also was de-
scribed as a TLR4-activating strain (15). These data suggest that
TLR4 activation and the downstream TRIF pathway are required
to initiate the signaling cascade involved in the upregulation of
Nos2 and NO production by macrophages infected with certain
strains ofM. tuberculosis that signal through TLR4 and are known
to induce type I IFN production by infected macrophages.
Type I IFN induces NO production by M. tuberculosis–infected
macrophages
Our data showed that some M. tuberculosis strains induce high
levels of Nos2 transcription and NO production by macrophages
by activating TLR4, whereas other strains only activate macro-
phages via TLR2. To investigate whether de novo protein synthesis
was required for maximal Nos2 induction by the TLR4-activating
strains, WT macrophages were infected with M. tuberculosis
BTB 02-171 strain in the absence or presence of cycloheximide
(an inhibitor of protein biosynthesis), and Nos2 transcription was
measured 6 h postinfection. Blockade of de novo protein syn-
thesis strongly inhibited Nos2 induction following macrophage
infection with the BTB 02-171 strain (Supplemental Fig. 2G),
indicating that specific mediators produced upon TLR4 stimu-
lation were required to induce Nos2 transcription in infected
macrophages. Thus, we investigated whether macrophage-derived
type I IFN might induce the production of NO in response to
M. tuberculosis by infecting WT and Ifnar2/2 macrophages
with the TLR4-activating BTB 02-171 strain. We found that NO
production was completely abrogated and Nos2 transcription
was greatly inhibited in the absence of type I IFN signaling
(Fig. 2E, Supplemental Fig. 2H). Other candidate mediators
produced downstream of TLR4 activation and with a described
role in the induction of NOS2 were also tested. Absence of IL-1R
signaling did not affect Nos2 transcription and only slightly re-
duced NO production by macrophages upon BTB 02-171 infection
(Supplemental Fig. 2I, 2J). Partial decreases in the expression of
Nos2 and NO production were detected in the absence of TNF
(Supplemental Fig. 2K, 2L), suggesting that TNF, although able to
modulate levels of these mediators, was not absolutely required to
induce NO production by BTB 02-171–infected macrophages.
FIGURE 1. Nos2 expression is essential for early
control of virulent M. tuberculosis growth and
immunopathology. WT and Nos22/2 mice were
infected withM. tuberculosis strains H37Rv (A and
C) or BTB 02-171 (B and D). (A and B) At the
indicated days postinfection, lung cell suspensions
were prepared, diluted, and plated onto 7H11 agar
to determine the number of mycobacterial CFU in
the lungs. Data points show the mean 6 SEM for
five mice per group. ***p , 0.001, two-way
ANOVA corrected for multiple comparisons with a
Bonferroni test. (C and D) H&E-stained lung tissue
from WT and Nos22/2 infected mice was analyzed
blindly at day 24 postinfection. Representatives of
one of five animals are shown (original magnifi-
cation 34; upper panels). Morphometric analysis
of the number and size of inflammatory lesions are
also shown (lower panels). Each bar represents
mean 6 SEM for five mice per group. Data are
representative of two independent experiments.
*p , 0.05, **p , 0.01, unpaired t test.
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FIGURE 2. Type I IFN induces Nos2 expression and NO production by M. tuberculosis–infected macrophages. (A–C) WT macrophages were infected
with M. tuberculosis strains H37Rv or BTB 02-171 (MOI = 2). (A) At the indicated hours postinfection, Nos2 mRNA levels were determined by quan-
titative real-time PCR and normalized to the expression of Hprt1. (B) Expression of NOS2 by uninfected (Ui) or infected macrophages was determined by
immunofluorescence at 8 h (green signal indicates NOS2 stain, and blue signal indicates cell nuclei). (C) NO production was determined by Griess reagent
assay of nitrites in culture supernatants at 24 h. WT, Tlr22/,2 and Tlr42/2 (D) or WT and Ifnar2/2 (E) macrophages were infected with BTB 02-171, and
NO levels in culture supernatants were determined by Griess reagent assay at 24 h. (F) WT macrophages were infected with H37Rv in the presence of
increasing concentrations of rIFN-b, and NO levels in culture supernatants were determined by Griess reagent assay at 24 h. (G) WT and Tlr42/2macrophages
were infected with BTB 02-171 in the presence or absence of rIFN-b, and NO levels in culture supernatants were determined by Griess reagent assay at
24 h. WT macrophages were infected with BTB 02-171 (H and I) or H37Rv (J and K) in the presence or absence of rIFN-b or rIFN-g. (H and J) NO
levels in culture supernatants were determined by Griess reagent assay at 24 h. (I and K) Nos2 mRNA levels were determined at the indicated hours post-
infection. (L) WT macrophages were infected with H37Rv in the presence of rIFN-g alone or rIFN-g plus rIFN-b, and NO levels in culture supernatants
were determined by Griess reagent assay at 24 h. Graphs show mean 6 SEM of triplicate samples. (M) WT, Tlr42/2, Ifnar2/2, and Nos22/2 mac-
rophages were infected with BTB 02-171 (MOI = 0.5) in the presence or absence of rIFN-g. Media were removed at 4 h postinfection, cells were washed in
PBS, and fresh media was replaced. At day 2 (left panel) and day 4 (right panel) postinfection, cells were washed in PBS and lysed in 0.2% saponin, and
bacterial loads were enumerated. Graphs show minimum to maximum CFU per well (five wells per experiment). Data are representative of at least two
independent experiments. Significance was determined using two-way ANOVA corrected for multiple comparisons with a Bonferroni test (A, I, and K), an
unpaired t test (C, H, L, and M), or one-way ANOVA with Bonferroni correction test (D, F, and J). Significance is relative to control group except in (K),
where significance is shown relative to H37Rv (*) or to H37Rv + IFN-b (#). *p , 0.05, **p , 0.01, ***p , 0.001, ###p , 0.001. BDL, below
detection level.
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Absence of IL-10 slightly reduced Nos2 transcription, but it did not
affect NO production by macrophages upon BTB 02-171 infection
(Supplemental Fig. 2M, 2N).
In further support of a role for type I IFN, addition of increasing
concentrations of rIFN-b to macrophages infected with the TLR2-
activating H37Rv laboratory strain resulted in significantly in-
creased NO production (Fig. 2F). Although NO production by
BTB 02-171–infected WT macrophages was not further enhanced
by IFN-b, NO production by Tlr42/2 macrophages was rescued
by the addition of IFN-b (Fig. 2G). Altogether, our findings in-
dicate that TLR4-dependent induction of type I IFN resulted in the
induction of NO production by macrophages in response to BTB
02-171 infection.
Type I and II IFNs differentially regulate Nos2 induction in
M. tuberculosis–infected macrophages
IFN-g is known as the major Nos2 regulator in M. tuberculosis
infection (11, 13, 47). We have now shown that the induction of
Nos2 transcription in M. tuberculosis–infected macrophages may
occur independently of IFN-g, via type I IFN signaling (Fig. 2,
Supplemental Fig. 2). Because both IFNs can induce Nos2 tran-
scription, we next investigated their relative contribution to NO
production in response to M. tuberculosis infection. We infected
WT macrophages with the BTB 02-171 strain in the presence of
rIFN-g at the time of infection. Enhanced NO production was
observed in infected macrophages treated with IFN-g (Fig. 2H).
Nos2 mRNA levels were also higher in infected macrophages
treated with IFN-g compared with untreated macrophages at 12 h
(Fig. 2I), although similar levels were detected at earlier times
postinfection (3 and 6 h). These findings suggest that both IFNs,
macrophage-derived type I IFN and exogenous IFN-g, may co-
operate for maximal Nos2 induction or that IFN-g may induce
higher levels of Nos2 than type I IFN upon M. tuberculosis in-
fection. To distinguish between these two possibilities, we in-
fected WT macrophages with the H37Rv strain and added IFN-b
or IFN-g at the time of infection. Although IFN-b and IFN-g
induced NO production by H37Rv-infected macrophages, IFN-g
was significantly more potent than maximal doses of IFN-b (Fig.
2J). Similar levels of Nos2 mRNA were induced by IFN-b and
IFN-g early postinfection (up to 6 h); however, although we ob-
served a plateau in Nos2 levels between 6 and 12 h postinfection
in the presence of IFN-b, IFN-g continued to increase the levels of
Nos2 transcription after 6 h postinfection (Fig. 2K). We showed
previously that type I IFN impairs IFN-g’s effects on cytokine
production byM. tuberculosis–infected macrophages (33). Therefore,
we examined whether type I IFN might affect IFN-g’s activation
of NO production by infected macrophages. WT macrophages
were infected with the H37Rv strain and concomitantly treated
with IFN-g alone or IFN-g plus IFN-b. NO production was reduced
slightly when both IFN-g and IFN-b were added to macrophages
compared with IFN-g alone (Fig. 2L), suggesting that, although
type I IFN itself can stimulate NO production by M. tuberculosis–
infected macrophages, it can also impair IFN-g–dependent in-
duction of NO production.
We next investigated whether type I IFN–induced Nos2 could
mediate restriction of M. tuberculosis in infected macrophages.
WT, Tlr42/2, Ifnar2/2, and Nos22/2 macrophages were infected
with the BTB 02-171 strain, in the presence or absence of IFN-g,
and bacterial loads were assessed 2 and 4 d postinfection (Fig. 2M).
Similar bacterial loads were detected at days 2 and 4 postinfection
among WT, Tlr42/2, Ifnar2/2, and Nos22/2 macrophages in the
absence of IFN-g (Fig. 2M). This suggests that TLR4 or type I
IFN signaling each did not induce bacterial clearance by infected
macrophages in vitro. IFN-g treatment induced a significant
reduction in bacterial load in WT, Tlr42/2, and Ifnar2/2 macro-
phages but not in Nos22/2 macrophages (Fig. 2M). Thus, Nos2-
dependent bacterial clearance by infected macrophages required the
presence of IFN-g. Altogether, our data highlight a differential
regulation of Nos2 transcription in M. tuberculosis–infected mac-
rophages by type I and type II IFNs; IFN-g is a more potent inducer
of NO production, by sustaining increased Nos2 transcription for
longer times postinfection, and this seems to be crucial for efficient
bacterial clearance by macrophages.
Type I IFN controls bacterial growth and immunopathology in
the lungs of mice infected with a virulentM. tuberculosis strain
in the absence of IFN-g signaling
The recent discovery of a protective role for type I IFN in
M. tuberculosis infection in the absence of IFN-g signaling (39),
together with our observation that induction of Nos2 by type I IFN
is masked by the dominant effect of IFN-g, led us to investigate
whether type I IFN might contribute to host protection by inducing
macrophage microbicidal mechanisms during M. tuberculosis in-
fection in vivo. To address this, we started by assessing the role
of type I and type II IFN signaling during infection with
M. tuberculosis strain BTB 02-171. To this end, Ifngr2/2 and Ifnar2/2
mice were intercrossed to obtain Ifngr2/2 3 Ifnar2/2 (dKO) mice.
WT, Ifnar2/2, Ifngr2/2, and dKO mice were aerosol infected with a
low-dose of virulentM. tuberculosis strain BTB 02-171. Similar to
the previous study with M. tuberculosis strain H37Rv (39), dKO
mice succumbed to BTB 02-171 infection significantly earlier
than did Ifngr2/2 mice (median survival, 32 versus 35 d, re-
spectively, p , 0.0025; Fig. 3A), whereas none of the WT or
Ifnar2/2 mice succumbed to disease, even at late stages of in-
fection (surviving .200 d; data not shown). In contrast to what
was reported with H37Rv infection, where bacterial loads were no
different in dKO mice compared with Ifngr2/2 mice (39), bacte-
rial loads were significantly higher in the lungs of dKO mice
compared with Ifngr2/2 mice at days 24 and 27 post–BTB 02-171
infection (Fig. 3B). This suggests that type I IFN also plays a role
in controlling bacterial growth in the absence of IFN-gR during
in vivo infection with the TLR4-activating M. tuberculosis strain
BTB 02-171. WT and Ifnar2/2 mice had lower lung bacterial loads
than did Ifngr2/2 and dKO mice, and no difference in bacterial
loads between WT and Ifnar2/2 mice was observed during the time
of the experiment (Fig. 3B) or at later time points (data not shown).
Tissue sections of infected lungs were examined to assess pulmo-
nary histology. Increased bacterial loads observed in the absence
of both type I and type II IFN receptors were accompanied by
enhanced lung pathology at day 27 post–BTB 02-171 infection
compared with Ifngr2/2 mice (Fig. 3C, 3D). The extent of the in-
flammatory infiltrates was significantly greater in dKO mice than in
single-KO and WTmice, showing extensive areas of granulomatous
inflammation (Fig. 3C, 3D). Enhanced lung pathology correlated
with increased numbers of neutrophils in the lungs of dKO and
Ifngr2/2 mice, whereas the number of other myeloid cell pop-
ulations was similar or reduced in the absence of IFN-gR but not
in dKO compared with Ifnar2/2 or WT mice (Fig. 4). This is in
keeping with the previous report by Desvignes et al. (39) using
M. tuberculosis strain H37Rv for infection.
Type I IFN suppresses expression of genes associated with
alternatively activated macrophages inM. tuberculosis–infected
lungs in the absence of IFN-g signaling
We next examined the contribution of each IFN pathway to the
induction of Nos2 transcription upon in vivo infection with
M. tuberculosis strain BTB 02-171. As expected, Nos2 expression
was significantly lower in infected lungs from Ifngr2/2 mice
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compared with WT mice at day 20 postinfection (Fig. 5A).
However, IFNAR signaling did not appear to contribute to Nos2
induction, because similar or increased levels of Nos2 were ob-
served between dKO and Ifngr2/2 mice or between Ifnar2/2 and
WT mice, respectively (Fig. 5A). Similarly, the number of NOS2-
expressing cells in infected lungs was not affected by the loss of
IFNAR signaling, but it was greatly reduced in the absence of
IFN-gR signaling (Supplemental Fig. 3A). These findings indicate
that the protective role of type I IFN during M. tuberculosis in-
fection, in the absence of IFN-g responses, did not correlate with
Nos2 expression in whole infected lungs.
It was shown that M. tuberculosis infection induces Arg1 ex-
pression in macrophages, which suppresses NOS2 activity and
M. tuberculosis killing by these cells (48). Indeed, mice lacking
ARG1 exhibit reduced bacterial burden compared with ARG1-
competent control mice (48, 49). Because NOS2 and ARG1 are
hallmarks of two extremes of macrophage polarization (classically
and alternatively activated macrophages, respectively) (50), we
hypothesized that the decrease in Nos2 expression in Ifngr2/2 and
dKO mice may be accompanied by an increased expression of
Arg1. Therefore, we measured Arg1 gene expression and ARG1
activity in the lungs of WT, Ifnar2/2, Ifngr2/2, and dKO mice
infected with M. tuberculosis strain BTB 02-171. Low levels of
Arg1 expression were detected in the lungs of WT and Ifnar2/2
mice at day 20 post–BTB 02-171 infection (Fig. 5B). Loss of IFN-
gR led to an increased expression of Arg1 in infected lungs
(Fig. 5B). Strikingly, loss of both type I and type II IFNRs resulted
in significantly higher Arg1 expression than that observed in the
absence of IFN-gR alone (Fig. 5B). Similarly, ARG1 activity was
significantly enhanced in the lungs of infected dKO mice com-
pared with Ifngr2/2 mice (Supplemental Fig. 3B), indicating that
type I IFN suppresses Arg1 gene expression and ARG1 activity in
the absence of IFN-gR. In addition, increased pulmonary ex-
pression of other markers associated with alternatively activated
macrophages, Ym1 and Fizz1, was detected in dKO mice com-
pared with Ifngr2/2, Ifnar2/2, and WT mice (Fig. 5C, 5D).
To further understand the molecular basis for the switch between
classically activated and alternatively activated macrophages ob-
served during M. tuberculosis infection in the absence of IFNAR
and IFN-gR, we measured the expression of several cytokines
previously associated with the control of macrophage polarization
(50, 51). Coincident with the increased expression of genes as-
sociated with alternatively activated macrophages (Fig. 5B–D), we
found decreased expression of Tnf, a cytokine associated with
classically activated macrophages (50, 51), in the lungs of infected
dKO mice compared with Ifngr2/2, Ifnar2/2, and WT mice
(Fig. 5E). Furthermore, the presence of markers associated with
alternatively activated macrophages also coincided with an in-
crease in mRNA expression of Th2 cytokines, such as IL-4, IL-5,
and IL-13, but not IL-10, in infected lungs in the absence of IFN-gR
that was enhanced significantly by the loss of IFNAR in the absence
of IFN-gR (Fig. 5F–I).
FIGURE 3. Type I IFN contributes to host protection during infection with virulent M. tuberculosis strain in the absence of IFN-gR. WT, Ifnar2/2,
Ifngr2/2, and Ifngr2/2 3 Ifnar2/2 (dKO) mice were infected with M. tuberculosis strain BTB 02-171. (A) Percentage of survival for three independent
experiments with 10 mice per group. xxp , 0.01, dKO versus Ifngr2/2 mice, log-rank test. (B) At the indicated days postinfection, lung cell suspensions
were prepared, diluted, and plated onto 7H11 agar to determine the number of mycobacterial CFU in the lungs. (C and D) H&E-stained tissue of infected
lungs at day 27 postinfection was analyzed blindly. (C) Representative images from one of five animals per group (original magnification 34). (D)
Morphometric analysis of the number and size of inflammatory lesions. Each bar represents mean 6 SEM for five mice per group. Data are representative
of two independent experiments. Significance was determined using two-way ANOVA (B) or one-way ANOVA (D), corrected for multiple comparisons
with a Bonferroni test. Significance is shown relative to WT (*), Ifnar2/2 (#), or Ifngr2/2 (x). *,#,xp , 0.05, **,##,xxp , 0.01, ***,###,xxxp , 0.001.
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Our data demonstrate that, in the absence of IFN-g signaling,
additional loss of type I IFN signaling results in very high levels
of expression of markers associated with alternatively activated
macrophages in infected lungs, which likely suppress bacterial
killing.
Type I IFN suppresses Arg1 expression in
M. tuberculosis–infected macrophages
To evaluate whether macrophage-derived type I IFN could have
a direct effect on suppressing Arg1 induction in response to
M. tuberculosis infection, we infected WTand Ifnar2/2macrophages
with M. tuberculosis strain BTB 02-171 and examined the sub-
sequent effects on Arg1 mRNA expression. This revealed that
macrophage-derived type I IFN suppressed Arg1 induction in in-
fected macrophages, because Arg1 levels were significantly higher
in Ifnar2/2 macrophages than in WT macrophages at 6 h post–
BTB 02-171 infection (Fig. 6A). Macrophage-derived TNF also
suppressed Arg1 induction in infected macrophages, because Arg1
levels were significantly higher in Tnf2/2 macrophages compared
with WT macrophages (Fig. 6B). Although loss of type I IFN
signaling decreased Tnf expression during in vivo infection in
the absence of IFN-gR (Fig. 5E), TNF production in response to
M. tuberculosis infection in vitro was not significantly different
between WT and Ifnar2/2 macrophages (Supplemental Fig. 4A).
Therefore, both type I IFN and TNF suppressed Arg1 expression
in infected macrophages, although the inhibition of Arg1 ex-
pression by type I IFN was not accompanied by increased levels
of TNF production in vitro. In contrast, macrophage-derived
IL-10 induced Arg1 expression in infected macrophages, because
Arg1 levels were significantly reduced in Il102/2 macrophages
compared with WT macrophages (Fig. 6C). Because type I IFN
and TNF induced Nos2 gene expression and NOS2 activity in
M. tuberculosis–infected macrophages (Fig. 2E, Supplemental Fig. 2H,
2K, 2L), we assessed whether suppression of Arg1 expression by
type I IFN and TNF was dependent on NOS2. Similar levels of
Arg1 expression were detected in Nos22/2 and WT macrophages
infected with the BTB 02-171 strain (Supplemental Fig. 4B), in-
dicating that suppression of Arg1 transcription by type I IFN and
TNF appeared to be independent of Nos2 induction or NOS2
activity. Taken together, our results show that type I IFN might
FIGURE 4. Type I and II IFNs regulate lung
myeloid cell recruitment during M. tuberculosis
infection. WT, Ifnar2/2, Ifngr2/2, and Ifngr2/2 3
Ifnar2/2 (dKO) mice were infected with the M.
tuberculosis strain BTB 02-17. Myeloid cell pop-
ulations in infected lungs were characterized by
flow cytometry 24 d postinfection. (A) Lung cells
were gated on single live cells using forward and
side scatter parameters. Gating strategy for quanti-
fication of myeloid cell populations is shown. R1
(CD11blo CD11c+): alveolar macrophages; R2
(CD11bhi CD11c+): myeloid dendritic cells (DCs);
gating on R3 (CD11bhi CD11cneg), R4 (CD11bhi
CD11cneg Ly6Clo/neg): recruited macrophages; R5
(CD11bhi CD11cneg Ly6Cint/hi Ly6Gneg): mono-
cytes; and R6 (CD11bhi CD11cneg Ly6Cint Ly6Ghi):
neutrophils. (B) Cell number of myeloid cell pop-
ulations. Each bar represents mean 6 SEM for five
mice per group. Data are a pool of two indepen-
dent experiments. Significance is shown relative to
WT (*), Ifnar2/2 (#), or Ifngr2/2 (x). **,##p , 0.01,
***,###p , 0.001, one-way ANOVA corrected for
multiple comparisons with a Bonferroni test.
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inhibit the differentiation of alternatively activated macrophages
by direct downregulation of Arg1 transcription inM. tuberculosis–
infected macrophages, although other factors further potentiate
this mechanism in vivo (Fig. 7).
Discussion
Type I IFN plays a role in M. tuberculosis persistence and TB
pathogenesis (16–30, 32, 33). However, in particular cases, such
as in multidrug resistant TB patients treated with antimycobacterial
drugs (52, 53) or in patients with mutations in their IFN-gR suf-
fering from mycobacterial infections (40, 54), type I IFN could
provide some level of protection. Thus, unraveling the molecular
mechanisms underlying this protective role may offer new targets
for host-direct therapies in these individuals. In the mouse model
of infection, a protective role was attributed to type I IFN, in the
absence of IFN-g–dependent immunity, by influencing the re-
cruitment and/or survival of potential target cells in infected
lungs (39). In this article, we describe a previously unappreciated
role for type I IFN in regulating macrophage activation during
M. tuberculosis infection, revealing a novel mechanism by which
type I IFN may confer protection against M. tuberculosis in-
fection in the absence of IFN-g signaling (Fig. 7). Our findings
demonstrate that type I IFN induces Nos2 and inhibits Arg1 ex-
pression following infection of macrophages with M. tuberculosis,
resulting in high NO production by infected macrophages. The
suppression of Arg1 expression by type I IFN, and indeed of other
FIGURE 5. Concomitant loss of type I and type II IFN signaling increases the expression of genes associated with alternatively activated macrophages in
M. tuberculosis–infected lungs. WT, Ifnar2/2, Ifngr2/2, and Ifngr2/2 3 Ifnar2/2 (dKO) mice were infected with theM. tuberculosis strain BTB 02-171. At
day 20 postinfection, RNA was extracted from infected lungs and Nos2 (A), Arg1 (B), Ym1 (C), Fizz1 (D), Tnf (E), Il4 (F), Il5 (G), Il13 (H), and Il10 (I)
mRNA expression was analyzed by quantitative real-time PCR and normalized to the expression of Hprt1, with the exception of Tnf, which was normalized
to Ubiquitin expression. Each bar represents mean 6 SEM for five mice per group. Data are representative of two independent experiments. Significance is
shown relative to WT (*), Ifnar2/2 (#), or Ifngr2/2 (x). *,#,xp , 0.05, **,##,xxp , 0.01, ***,###,xxxp , 0.001, one-way ANOVA corrected for multiple
comparisons with a Bonferroni test.
FIGURE 6. Type I IFN and TNF suppress Arg1 tran-
scription in macrophages infected with M. tuberculosis.
WT and Ifnar2/2 (A), WT and Tnf2/2 (B), or WT and
Il102/2 (C) macrophages were infected with BTB
02-171 (MOI = 2), and Arg1 mRNA levels were de-
termined by quantitative real-time PCR at 6 h post-
infection and normalized to the expression of Hprt1.
Graphs show mean 6 SEM of triplicate samples. Data
are representative of at least two independent ex-
periments. *p , 0.05, **p , 0.01, ***p , 0.001,
unpaired t test.
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genes associated with alternatively activated macrophages, was
also observed during in vivo infection in the absence of IFN-g
signaling. These alterations correlated with control of bacterial
growth and pathology. Taken together, our data show that, al-
though masked by the dominant effect of IFN-g, type I IFN
has a regulatory function in macrophage activation during
M. tuberculosis infection; it contributes to host protection by sup-
pressing the switching of macrophages from a more protective,
classically activated phenotype to a more permissive, alternatively
activated phenotype.
Mutations in both IFN-gR chains, IFNGR1 and IFNGR2, were
identified in humans and have been associated with increased
susceptibility to mycobacterial infections (9). It was reported that
adjunctive treatment with IFN-a confers clinical benefits in pa-
tients with mutations in the IFN-gR who are suffering from my-
cobacterial diseases (40, 54). Our results provide important
information that may help to explain the mechanism underlying
the beneficial effect of IFN-a treatment and provide novel targets
for host-directed therapy to improve future treatment of patients
with IFN-gR mutations or with compromised IFN-g responses.
NO synthesis by NOS2 is critical for effective immunity and host
protection against virulent strains of M. tuberculosis (12–14, 41,
55). Although M. tuberculosis strain BTB 02-171 induces strong
Nos2 expression early after in vivo infection, this strain still causes
severe disease, as shown by increased bacterial loads and en-
hanced lung pathology (15). In some bacterial infections, an ex-
acerbated expression of NOS2 was associated with a more severe
disease outcome, likely due to NO-mediated cytotoxicity and
tissue damage and suppression of the immune response to the
pathogen (43–45). Although we cannot completely exclude the
hypothesis that elevated Nos2 expression can contribute to disease
severity during infection with M. tuberculosis strain BTB 02-171,
mice deficient for NOS2 were extremely susceptible to infection
with this strain. Additionally, compared with the less virulent
laboratory strain H37Rv, Nos22/2 mice showed earlier suscepti-
bility to BTB 02-171 infection that correlates with earlier induc-
tion of elevated levels of Nos2 expression following infection with
this strain. Temporal differences in Nos2 induction following in-
fection with different strains of M. tuberculosis may explain
previous reports showing a protective role for NOS2 during the
late, but not the early, phase of infection (41).
Surprisingly, we found that the expression of Nos2 in macro-
phages infected with M. tuberculosis strain BTB 02-171 was in-
dependent of the presence of IFN-g, a key cytokine for activation
of macrophages during M. tuberculosis infection to produce large
amounts of NO (11, 13, 47, 56). We then investigated the mo-
lecular mechanisms underlying this IFN-g–independent Nos2 in-
duction and NO production and found a requirement for TLR4/
TRIF signaling. Type I IFN was reported to contribute to the in-
duction of NO production following stimulation of macrophages
with the TLR4 ligand LPS (57). We found that type I IFN sig-
naling was required for transcriptional induction of Nos2 and
consequent NO production in macrophages infected with BTB 02-
171. Furthermore, addition of IFN-b significantly enhanced NO
production following infection with the H37Rv strain, which, on
its own, induced little production of NO by infected macrophages.
Nevertheless, our results show that IFN-g is a stronger inducer
of NO production by M. tuberculosis–infected macrophages than
type I IFN, likely due to prolonged transcriptional induction of
Nos2. Furthermore, IFN-g–induced NOS2, but not type I IFN–
induced NOS2, appears to be required for efficient bacterial
control by macrophages. We reported previously that type I IFN
impairs IFN-g’s effects on cytokine production by macrophages
infected with M. tuberculosis (33). Type I IFN completely abro-
gated the ability of IFN-g to enhance IL-12 and TNF production
and to inhibit IL-10 production by macrophages in response to
H37Rv infection, although it did not impair IFN-g inhibition of
IL-1b production (33). We now show that type I IFN can also
downregulate IFN-g–dependent induction of NO production by
infected macrophages. Because IFN-g–dependent inhibition of
IL-1b production during M. tuberculosis infection seems to be me-
diated by Nos2 (33, 58), our recent finding may explain why the
ability of IFN-g to suppress IL-1b production by infected mac-
rophages was indeed increased by the presence of type I IFN (33).
Although IL-10 is an important mediator of the suppressive effect
of type I IFN on IL-12 and TNF macrophage production induced
by IFN-g, IL-10 did not play a role in suppressing the IFN-g–
dependent induction of NO production by M. tuberculosis–
infected macrophages (data not shown).
We report in this article that, in vivo, Nos2 expression required
IFN-g signaling because Nos2 mRNA levels were significantly
lower in infected lungs from mice deficient for IFN-gR compared
FIGURE 7. Schematic summary of the regulation of macrophage activation by type I IFN duringM. tuberculosis infection. (A and B) Activation of TLR4
in macrophages by specific M. tuberculosis strains leads to the production of type I IFN, in addition to other cytokines (e.g., TNF) (15). Type I IFN induces
Nos2 and inhibits Arg1 gene expression and protein activity in infected macrophages, thus regulating macrophage activation toward a more protective
phenotype. Induction of Nos2 and suppression of Arg1 transcription in infected macrophages are further potentiated by macrophage-derived TNF. In vivo,
in the absence of IFN-g signaling, type I IFN suppresses the expression of markers associated with alternatively activated macrophages following
M. tuberculosis infection, likely by direct regulation of macrophage activation, as well as by modulating TNF and Th2-associated cytokine expression,
contributing to host protection.
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with WT mice, in agreement with previous reports (11, 13, 32).
Type I IFN inhibited IFN-g–induced Nos2 transcription slightly, in
line with our in vitro data and with another study reporting an
IFNAR-mediated inhibition of IFN-g–induced NOS2 expression
in lung myeloid cells (32). However, type I IFN–dependent Nos2
induction was not detected in infected lungs at the time points
analyzed postinfection. One explanation is that type I IFN–induced
Nos2 transcription is transient and not sustained over time, in
contrast to IFN-g–dependent Nos2 induction. This hypothesis is
supported by our in vitro data showing that, although both type I
and type II IFNs induced similar levels of Nos2 early following
macrophage infection, increased levels of Nos2 were only sustained
over time in the presence of IFN-g. Nos2 induction was reported to
be critical to control neutrophil-mediated pulmonary pathology
following M. tuberculosis infection (58). Therefore, induction of
Nos2 by type I IFN (even if transient or in low levels) could explain
the increased numbers of neutrophils and enhanced lung pathology
observed in the absence of both IFN-gR and IFNAR. In addition to
enhanced pathology, we observed increased lung bacterial loads in
the absence of both IFN-gR and IFNAR, compared with the ab-
sence of IFN-gR alone, which contrasts with a previous study of
M. tuberculosis strain H37Rv (39). The strain of M. tuberculosis
used in this study, BTB 02-171, is more virulent and induces higher
levels of type I IFN in the lungs of infected mice than does the
H37Rv strain (15), which may account for some of the differences
observed between the previous study and ours (39).
The increased susceptibility to M. tuberculosis infection that we
observed in the absence of both IFN-gR and IFNAR signaling
correlated with increased expression levels of genes associated
with alternatively activated macrophages, such as Arg1, Ym1, and
Fizz1, in the lungs. A positive correlation between ARG1 and
human TB was suggested recently based on the increased ex-
pression of ARG1 in monocytes isolated from peripheral blood of
patients with active TB compared with those with latent TB (49).
ARG1 was also reported to be expressed in granuloma-associated
macrophages of lung tissues from patients with TB (59). Likewise,
M. tuberculosis infection can induce Arg1 expression in murine
macrophages (48, 60), and specific elimination of Arg1 in macro-
phages decreased lung bacterial loads during in vivo infection (48,
49). How macrophage expression of Arg1 during M. tuberculosis
infection increases susceptibility to M. tuberculosis infection re-
mains unclear. It was suggested that ARG1 impairs bacterial growth
restriction by infected macrophages by suppressing NOS2 activity
and preventing NO production (48), which could be part of the
mechanism observed in our study ofM. tuberculosis infection in the
absence of IFN-gR and IFNAR signaling. As another mechanism,
we consider the possibility that ARG1 activity may supply sub-
strates forM. tuberculosis growth and survival, as was suggested for
Leishmania species (61).
Alternative macrophage activation is typically induced by
IL-4Ra activation (50, 51). Differentiation of alternatively activated
macrophages with IL-4 in vitro was reported to inhibit macro-
phage antimicrobial responses toM. tuberculosis (62). Moreover,
Th2 cell responses were associated with TB pathogenesis by
mediating the alternative activation of macrophages during
M. tuberculosis infection (49, 63, 64). We detected increased levels
of Th2-associated cytokines in infected lungs in the absence of
IFN-gR, which were further enhanced by the concomitant absence
of IFNAR, suggesting that increased IL-4Ra signaling may drive
alternative activation of lung macrophages in Ifngr2/2 and dKO
mice. In addition, decreased levels of TNF expression were de-
tected in the absence of both IFN-gR and IFNAR. TNF was re-
cently shown to hamper alternative activation of macrophages in
murine models of cancer by suppressing Th2-associated cytokine
expression (65). Although the effect of TNF on the expression of
Th2-associated cytokines remains to be clarified in our in vivo
model, our data show that TNF directly inhibits Arg1 expression
in M. tuberculosis–infected macrophages. In contrast, IL-10 is re-
quired for maximal induction of Arg1 expression inM. tuberculosis–
infected macrophages in vitro. Overexpression of IL-10 by
macrophages and monocytes (under control of the CD68 pro-
moter) was shown to induce the expression of Arg1 and other
markers associated with alternative macrophage activation during
M. tuberculosis infection, increasing host susceptibility to TB
(66). However, similar levels of IL-10 expression were detected in
infected lungs in the presence or absence of IFN-gR and IFNAR,
suggesting that IL-10 does not play a major role in the regulation
of Arg1 expression in our in vivo model. Type I IFN inhibits Arg1
expression by infected macrophages in our in vitro model, in
which Th2-associated cytokines are absent, and TNF production
was not affected by the absence of IFNAR. These findings point to
a direct suppressor function of type I IFN on the transcriptional
induction of Arg1 in macrophages following M. tuberculosis in-
fection. Therefore, during in vivo infection, Arg1 expression
may be directly inhibited by type I IFN signaling and indirectly
inhibited by type I IFN–dependent regulation of TNF and Th2-
associated cytokine expression.
In summary, our findings demonstrate that inhibition of alter-
native macrophage activation by type I IFN correlates with control
of bacterial growth and pathology during infection with a virulent
strain of M. tuberculosis in the absence of IFN-gR. Type I IFN
inhibits transcriptional induction of Arg1 in infected macrophages.
Moreover, in the absence of IFN-gR, IFNAR signaling inhibits the
expression of Th2-associated cytokines and enhances TNF ex-
pression in infected lungs, which likely further contributes to the
suppression of alternative macrophage activation in vivo. In ad-
dition to furthering our understanding of the modulation of mac-
rophage activation during M. tuberculosis infection, these data
provide evidence for a novel mechanism by which type I IFN, in
the absence of IFN-gR, may confer protection againstM. tuberculosis
infection; this offers new avenues to develop host-direct thera-
pies for patients with compromised IFN-g responses.
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